Sarepta's Duchenne gene therapy wins conditional approval; FDA moves to stop vape shops from selling Elf Bar, Esco Bars

The FDA restricted Sarepta's treatment to younger patients, with additional data required to broaden its use.

June 22, 2023 Check out STAT+

Sponsored By

Kristoffer Tripplaar/Sipa via AP STAT+ | FDA grants conditional approval to Sarepta's gene therapy for Duchenne muscular dystrophy Regulators restricted the treatment to younger patients, with additional data required to broaden its use. By Jason Mast and Adam Feuerstein STAT+ | The strategy behind the pharmaceutical industry's flurry of lawsuits challenging drug pricing reform Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. By Rachel Cohrs FDA moves to stop vape shops from selling Elf Bar, Esco Bars The FDA is ramping up its efforts to force vape shops and other retailers to stop selling Elf Bar and Esco Bars products. By Nicholas Florko Adobe A 988 operator, faced with a flood of calls, turns to AI to boost counselor skills As demands on crisis lines soar, AI evaluations may help 988 hotline counselors improve how they respond to crises. By Mario Aguilar House GOP inquiry over gain-of-function research targets a scientific giant For more than 50 years, Bernard Moss has been probing viruses in relative anonymity — except, that is, among the virological cognoscenti. By Helen Branswell STAT+ | Doctors' lobby doubles down on the fight against expanding open access to research When subscribers stop paying for journal access, where is the money to keep the journals running going to come from? By Brittany Trang Skip Van Orden/CDC via AP A looming penicillin shortage threatens pregnant adults with syphilis and their newborns Pfizer expects to run out of a key form of penicillin in the near future. It's the only drug safe enough for pregnant adults with syphilis. By Bree Iskandar and Abdullahi Tsanni Listen: Messy PBM conflicts, debatable vaccines, & the future of flu season STAT's Bob Herman joins us to explain his investigation into some brazen conflicts of interest in the world of prescription drug pricing. By Damian Garde and Meg Tirrell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser